Start-Up Mitochon's Repurposed Drug Targets Mitochondria For Orphan Diseases
Emerging Company Profile: Mitochon Pharmaceuticals, founded in 2014, focuses on mitochondrial therapeutics with emphasis on neurodegenerative diseases. CEO Robert Alsonso outlines the biotech's corporate strategy now that an orphan drug designation has been given to lead drug MP-101 for Huntington’s Disease.
You may also be interested in...
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.